Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Total Current Liabilities: 2022-2024

Historic Total Current Liabilities for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to $73.5 million.

  • Day One Biopharmaceuticals' Total Current Liabilities rose 42.07% to $56.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.5 million, marking a year-over-year increase of 42.07%. This contributed to the annual value of $73.5 million for FY2024, which is 148.92% up from last year.
  • Per Day One Biopharmaceuticals' latest filing, its Total Current Liabilities stood at $73.5 million for FY2024, which was up 148.92% from $29.5 million recorded in FY2023.
  • In the past 5 years, Day One Biopharmaceuticals' Total Current Liabilities ranged from a high of $73.5 million in FY2024 and a low of $16.6 million during FY2022.
  • Its 3-year average for Total Current Liabilities is $39.9 million, with a median of $29.5 million in 2023.
  • Data for Day One Biopharmaceuticals' Total Current Liabilities shows a peak YoY spiked of 148.92% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Day One Biopharmaceuticals' Total Current Liabilities stood at $16.6 million in 2022, then soared by 77.60% to $29.5 million in 2023, then spiked by 148.92% to $73.5 million in 2024.